Laronidase
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Laronidase
- Laronidase: From Mucopolysaccharidosis Type I to Lysosomal Storage Disease with Skeletal Involvement
Laronidase: From Mucopolysaccharidosis Type I to Lysosomal Storage Disease with Skeletal Involvement
One-Sentence Summary
Laronidase is a recombinant alpha-L-iduronidase enzyme replacement therapy, originally used for mucopolysaccharidosis type I (MPS I), including Hurler, Hurler-Scheie and Scheie syndromes. The TxGNN model predicts it may be effective for lysosomal storage disease with skeletal involvement, but there are currently no registered clinical trials and only 4 publications for this prediction, none of which directly test the new indication. The predicted category largely overlaps with the already-approved MPS I indication, so this is best seen as a research question rather than a true new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mucopolysaccharidosis I (Hurler, Hurler-Scheie and Scheie syndromes). The Singapore licence text does not state an indication. |
| Predicted New Indication | Lysosomal storage disease with skeletal involvement |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Laronidase is a recombinant form of alpha-L-iduronidase, the lysosomal enzyme that is deficient in MPS I. Replacing it helps break down the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, which otherwise accumulate in tissues. Currently, detailed mechanism of action data is not available in the compiled data, but this role is well described in the literature.
MPS I causes skeletal disease (dysostosis multiplex) through GAG accumulation. A laboratory study (PMID 18758061) showed that cultured fibroblasts and osteoblasts take up laronidase, mainly through mannose 6-phosphate receptors, and that the enzyme reaches lysosomes. This supports a plausible effect on bone cells.
There are important caveats. The predicted category is a broad class label that overlaps with the approved MPS I indication, rather than a distinct new disease. Enzyme replacement is also known to have limited effect on bone and cartilage because of poor penetration into avascular tissue. Because laronidase is specific to iduronide substrates, efficacy in other storage diseases is not expected.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25345091 | 2014 | Review | Pediatr Endocrinol Rev | Overview of MPS I: iduronidase deficiency, the Hurler/Hurler-Scheie/Scheie spectrum, and diagnosis by urinary GAGs and enzyme assay |
| 12196045 | 2002 | Review | BioDrugs | Early development of laronidase for MPS I, including orphan designation and fast-track status |
| 23127271 | 2012 | Case report | Pediatr Neurol | 6.5-year follow-up of a boy with Scheie syndrome on enzyme replacement; overall status declined and disease progressed |
| 18758061 | 2008 | In vitro study | Biol Pharm Bull | MPS I fibroblasts and osteoblasts took up laronidase via M6P receptors, and the enzyme reached lysosomes |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13347P | ALDURAZYME | Injection, solution | Not stated in the available licence record |
Safety Considerations
- Drug Interactions: Two minor interactions were identified, with chloroquine and procaine.
For other safety information, including warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output and indirect MPS I literature, with no trials directly addressing the new indication. The predicted category also largely overlaps with the approved MPS I use, and enzyme replacement is known to have limited effect on bone. It is best treated as a research question.
To proceed, the following is needed:
- Clarification of what "lysosomal storage disease with skeletal involvement" covers beyond MPS I, and whether any distinct population is not already served by the approved indication
- Studies of skeletal outcomes with laronidase
- The package insert for warnings, contraindications and the approved indication text
- Mechanism of action data
Other Predicted Indications (Brief)
For completeness, the other nine model predictions all carry weaker evidence:
- Sanfilippo syndrome (99.22%, L4, Hold): Sanfilippo syndrome (MPS III) is caused by deficiencies in other heparan sulfate-degrading enzymes, which laronidase cannot replace. The retrieved literature concerns MPS I, and intravenous enzyme replacement has limited CNS penetration.
- Lysosomal disease with hypertrophic cardiomyopathy (98.82%, L5, Hold): Model prediction only, with no trials or literature.
- Syndromic neurometabolic disease with X-linked intellectual disability (98.73%, L5, Hold): Prediction only, with unclear mechanistic link.
- Eyelid and ocular malformation syndromes (ranks 5, 6, 7, 9 and 10), and inborn disorder of lysosomal amino acid transport (rank 8, L5, Hold): Prediction only, with no plausible mechanism and likely driven by network similarity.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.